Mirrors of Medicine shared a post on LinkedIn:
“Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America
CDK4/6 inhibitors have transformed treatment of hormone receptor–positive, HER2-negative advanced Breast Cancer, yet their use in Latin America varies.
In a survey of 116 oncologists across 15 countries, ribociclib was most preferred, while abemaciclib and palbociclib were selected for specific clinical scenarios. Despite broad national availability, institutional access remained uneven, particularly between private and public settings.
Expanding public access and generating real-world data are essential to improve equity and outcomes.”
Sergio Cifuentes-Canaval, Medical Oncologist at Las Américas Auna Clinic, shared Mirrors of Medicine’s post, adding:
“My congratulations to Andres Meraz Brenez, Cynthia Villarreal Garza for this wonderful effort.”
Title: Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America
Authors: Cynthia Villarreal-Garza, Andres Meraz-Brenez, Agatha Reyes Morales, Ahmad Wali Mushtaq, Brizio Moreno-Jaime, Denis U. Landaverde, Fernando E. Petracci, Henry Idrobo Quintero, Joel Moreno Ríos, Juan Carlos Samamé Pérez-Vargas, Victor Acosta Marín, William Armando Mantilla, Alejandro Aranda-Gutierrez, Daniela Vazquez-Juarez
Read the Full Article.
More posts about Mirrors of Medicine on OncoDaily.